No Data
No Data
Express News | Shanghai Junshi Biosciences - Unit Granted Certificate of Drug/Product Registration Issued by Pharmacy and Poisons Board of Hong Kong
Junshi Bio (01877.HK): Toripalimab has been approved for listing in China Hong Kong.
On October 15th, Junshi Bio (01877.HK) announced that its wholly-owned subsidiary, Topalliance Biosciences Hong Kong Limited, recently obtained the 'Drug/Product Registration Certificate' issued by the Pharmacy and Poisons Board (PPB) in Hong Kong. The certificate approves a combination of Toripalimab (commodity name in Hong Kong: LOQTORZI) with cisplatin/gemcitabine as first-line treatment for adult patients with metastatic or recurrent locally advanced nasopharyngeal carcinoma, as well as monotherapy.
Express News | Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR
junshi bio (688180.SH): Toripalimab monoclonal antibody approved for listing in Hong Kong, the first and only immunotherapy drug for nasopharyngeal carcinoma tumors.
junshi bio (688180.SH) announced that its wholly-owned subsidiary, Topallai Biomedical Hong Kong Limited...
Shanghai Junshi Biosciences' Cholesterol Drug Gets NDA From NMPA; Shares Down 5%
junshi bio (688180.SH): The new drug application for Angoriximab injection was approved.
JUNSHI BIO (688180.SH) announced on October 11th that the company learned from the website of the National Medical Products Administration that the NMPA approved the company's application for the commercialization of Angoriximab injection (recombinant humanized anti-PCSK9 monoclonal antibody injection, trade name: JUNSHIDA) for the treatment of primary hypercholesterolemia (non-familial) and diversified bond lipid abnormalities in adults. This is the company's fifth approved commercial product. Indications: In addition to dietary control, in combination with statins, or in combination with statins and ezetimibe, for use in moderate to moderate dose.
No Data
No Data